TD Cowen Maintains Amgen(AMGN.US) With Buy Rating, Raises Target Price to $383
Dow Drops 138 Points On Losses For Shares Of American Express, Merck
Express News | Amgen Says FDA Shifted the Pdufa Date by 3 Months to Jan 17, 2025 to Allow Additional Time for Review of Supplemental Data Recently Submitted to Agency
Express News | Amgen Says FDA Has Extended Review Period for Lumakras in Combination With Vectibix for Treating Some Colorectal Cancer Patients
Consumer, Labor Groups Urge FTC to Block Catalent Sale to Novo Nordisk - Report
Bernstein: First time covering eli lilly and co, gilead sciences and amgen, all with an "outperform large cap" rating.
Bernstein initiates coverage on eli lilly and co, gilead sciences, and amgen with an "outperform" rating. Bernstein stated that the bullish ratings on gilead and amgen are based on optimistic expectations for revenue growth from key assets from now until 2030, including gilead's HIV PreEP treatment lenacapavir, amgen's weight loss drug MariTide, and rare disease investment portfolio. As for eli lilly and co, Bernstein stated that the rating "depends on how it uses the cash generated from weight loss drugs", eli lilly and co is ready to leverage a diversified investment portfolio and drive growth through weight loss drugs. In addition, Bern